Symbols / URGN Stock $24.11 -0.82% UroGen Pharma Ltd.

Healthcare • Biotechnology • United States • NGM
URGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Ms. Elizabeth A. Barrett
Exch · Country NGM · United States
Market Cap 1.17B
Enterprise Value 1.18B
Income -153.49M
Sales 109.79M
FCF (ttm) -99.42M
Book/sh -2.18
Cash/sh 2.47
Employees 291
Insider 10d —
IPO May 04, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 20.58
PEG —
P/S 10.69
P/B -11.05
P/C —
EV/EBITDA -9.50
EV/Sales 10.78
Quick Ratio 3.31
Current Ratio 4.01
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -3.19
EPS next Y 1.17
EPS Growth —
Revenue Growth 54.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-12
Earnings (prior) 2026-03-02
ROA -32.10%
ROE —
ROIC —
Gross Margin 88.66%
Oper. Margin -50.52%
Profit Margin -139.81%
Shs Outstand 48.68M
Shs Float 38.66M
Insider Own 3.75%
Instit Own 98.41%
Short Float 16.32%
Short Ratio 10.98
Short Interest 7.83M
52W High 30.00
vs 52W High -19.63%
52W Low 3.42
vs 52W Low 604.97%
Beta 1.44
Impl. Vol. 39.80%
Rel Volume 0.73
Avg Volume 804.14K
Volume 585.36K
Target (mean) $33.88
Tgt Median $34.50
Tgt Low $17.00
Tgt High $40.00
# Analysts 8
Recom Strong_buy
Prev Close $24.31
Price $24.11
Change -0.82%
About

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$33.88
Mean price target
2. Current target
$24.11
Latest analyst target
3. DCF / Fair value
$-36.76
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$24.11
Low
$17.00
High
$40.00
Mean
$33.88

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-31 main D. Boral Capital Buy → Buy $33
2026-03-02 main D. Boral Capital Buy → Buy $33
2026-01-23 main D. Boral Capital Buy → Buy $33
2026-01-05 main D. Boral Capital Buy → Buy $33
2025-10-27 reit HC Wainwright & Co. Buy → Buy $40
2025-10-27 main D. Boral Capital Buy → Buy $25
2025-10-03 main D. Boral Capital Buy → Buy $25
2025-08-19 init Piper Sandler — → Overweight $36
2025-08-11 main HC Wainwright & Co. Buy → Buy $40
2025-08-07 main D. Boral Capital Buy → Buy $25
2025-08-05 main D. Boral Capital Buy → Buy $25
2025-07-08 reit HC Wainwright & Co. Buy → Buy $50
2025-07-07 main D. Boral Capital Buy → Buy $25
2025-06-16 up HC Wainwright & Co. Neutral → Buy $50
2025-06-13 main Scotiabank Sector Outperform → Sector Outperform $47
2025-06-13 main Guggenheim Buy → Buy $30
2025-06-13 main Oppenheimer Outperform → Outperform $31
2025-06-12 main D. Boral Capital Buy → Buy $25
2025-06-03 main Oppenheimer Outperform → Outperform $10
2025-05-23 main Guggenheim Buy → Buy $15
News
RSS: Latest URGN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-02-03 SCHOENBERG MARK Officer — 7,373 $19.69 $145,174
2026-02-03 SMITH JASON DREW General Counsel — 7,479 $19.69 $147,262
2026-01-30 SCHOENBERG MARK Officer — 13,333 — —
2026-01-30 SMITH JASON DREW General Counsel — 15,500 — —
2025-11-26 BUTITTA CYNTHIA M Director — 2,000 — —
2025-11-26 ROBINSON JAMES A JR. Director — 2,000 — —
2025-11-26 HOLDEN STUART M.D. Director — 2,000 — —
2025-11-26 WEN LEANA Director — 2,000 — —
2025-11-26 WILDMAN DANIEL GEORGE Director — 2,000 — —
2025-11-19 SCHOENBERG MARK Officer — 10,000 $25.00 $250,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
109.79
+21.45%
90.40
+9.29%
82.71
+28.52%
64.36
Operating Revenue
109.79
+21.45%
90.40
+9.29%
82.71
+28.52%
64.36
Cost Of Revenue
12.45
+40.15%
8.88
-5.13%
9.36
+22.30%
7.65
Reconciled Cost Of Revenue
12.45
+40.15%
8.88
-5.13%
9.36
+22.30%
7.65
Gross Profit
97.34
+19.41%
81.52
+11.13%
73.35
+29.36%
56.70
Operating Expense
222.20
+24.62%
178.30
+28.38%
138.89
+2.32%
135.74
Research And Development
67.11
+17.43%
57.15
+25.28%
45.61
-13.78%
52.91
Selling General And Administration
155.10
+28.02%
121.15
+29.89%
93.27
+12.60%
82.84
Total Expenses
234.65
+25.36%
187.18
+26.26%
148.25
+3.38%
143.40
Operating Income
-124.86
-29.01%
-96.78
-47.68%
-65.54
+17.09%
-79.04
Total Operating Income As Reported
-124.86
-29.01%
-96.78
-47.68%
-65.54
+17.09%
-79.04
EBITDA
-135.66
-22.95%
-110.33
-34.71%
-81.90
+16.23%
-97.77
Normalized EBITDA
-135.66
-22.95%
-110.33
-34.71%
-81.90
+16.23%
-97.77
Reconciled Depreciation
2.41
+103.29%
1.19
-30.44%
1.71
-6.16%
1.82
EBIT
-138.07
-23.81%
-111.52
-33.38%
-83.61
+16.05%
-99.59
Total Unusual Items
—
-23.41
-8.63%
-21.55
+0.03%
-21.56
Total Unusual Items Excluding Goodwill
—
-23.41
-8.63%
-21.55
+0.03%
-21.56
Net Income
-153.49
-20.98%
-126.87
-24.09%
-102.24
+6.87%
-109.78
Pretax Income
-153.42
-23.68%
-124.04
-26.16%
-98.32
+8.98%
-108.03
Net Non Operating Interest Income Expense
-27.88
-3.15%
-27.03
+19.61%
-33.63
-15.72%
-29.06
Interest Expense Non Operating
15.35
+22.55%
12.52
-14.91%
14.71
+74.39%
8.44
Net Interest Income
-27.88
-3.15%
-27.03
+19.61%
-33.63
-15.72%
-29.06
Interest Expense
15.35
+22.55%
12.52
-14.91%
14.71
+74.39%
8.44
Interest Income Non Operating
5.96
-32.99%
8.90
+237.03%
2.64
+181.56%
0.94
Interest Income
5.96
-32.99%
8.90
+237.03%
2.64
+181.56%
0.94
Other Income Expense
-0.67
-192.58%
-0.23
-127.33%
0.84
+1063.89%
0.07
Other Non Operating Income Expenses
-0.67
-192.58%
-0.23
-127.33%
0.84
+1063.89%
0.07
Gain On Sale Of Security
—
-23.41
-8.63%
-21.55
+0.03%
-21.56
Tax Provision
0.08
-97.25%
2.83
-27.76%
3.92
+123.36%
1.75
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-153.49
-20.98%
-126.87
-24.09%
-102.24
+6.87%
-109.78
Net Income From Continuing Operation Net Minority Interest
-153.49
-20.98%
-126.87
-24.09%
-102.24
+6.87%
-109.78
Net Income From Continuing And Discontinued Operation
-153.49
-20.98%
-126.87
-24.09%
-102.24
+6.87%
-109.78
Net Income Continuous Operations
-153.49
-20.98%
-126.87
-24.09%
-102.24
+6.87%
-109.78
Normalized Income
-153.49
-20.98%
-126.87
-24.09%
-102.24
+6.87%
-109.78
Net Income Common Stockholders
-153.49
-20.98%
-126.87
-24.09%
-102.24
+6.87%
-109.78
Diluted EPS
-3.19
-7.77%
-2.96
+16.62%
-3.55
+25.89%
-4.79
Basic EPS
-3.19
-7.77%
-2.96
+16.62%
-3.55
+25.89%
-4.79
Basic Average Shares
48.12
+12.22%
42.88
+48.70%
28.83
+26.43%
22.81
Diluted Average Shares
48.12
+12.22%
42.88
+48.70%
28.83
+26.43%
22.81
Diluted NI Availto Com Stockholders
-153.49
-20.98%
-126.87
-24.09%
-102.24
+6.87%
-109.78
Total Other Finance Cost
18.50
-20.96%
23.41
+8.63%
21.55
-0.03%
21.56
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
200.46
-29.84%
285.71
+60.23%
178.31
+31.48%
135.62
Current Assets
186.02
-32.63%
276.13
+63.21%
169.19
+31.25%
128.91
Cash Cash Equivalents And Short Term Investments
120.46
-49.11%
236.69
+72.80%
136.97
+37.02%
99.96
Cash And Cash Equivalents
110.75
-35.61%
171.99
+81.04%
95.00
+71.46%
55.41
Other Short Term Investments
9.71
-84.99%
64.70
+54.17%
41.97
-5.81%
44.56
Receivables
33.08
+62.95%
20.30
+31.46%
15.44
+21.56%
12.70
Accounts Receivable
33.08
+62.95%
20.30
+31.46%
15.44
+21.56%
12.70
Inventory
16.46
+78.43%
9.23
+62.65%
5.67
+31.17%
4.33
Raw Materials
11.04
+133.74%
4.72
+70.91%
2.76
+21.44%
2.28
Finished Goods
5.42
+19.90%
4.52
+57.18%
2.88
+42.50%
2.02
Prepaid Assets
—
—
—
—
Restricted Cash
1.35
+25.46%
1.08
+31.06%
0.82
+0.98%
0.81
Other Current Assets
14.67
+65.88%
8.85
-13.97%
10.28
-7.39%
11.10
Total Non Current Assets
14.43
+50.70%
9.58
+4.94%
9.12
+35.95%
6.71
Net PPE
9.09
+139.98%
3.79
+60.55%
2.36
-37.05%
3.75
Gross PPE
13.68
+69.52%
8.07
+27.85%
6.31
-8.51%
6.90
Accumulated Depreciation
-4.59
-7.15%
-4.28
-8.32%
-3.95
-25.46%
-3.15
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
3.41
+8.15%
3.15
+8.57%
2.90
+4.87%
2.77
Other Properties
9.64
+124.78%
4.29
+53.76%
2.79
-20.56%
3.51
Leases
0.63
+0.00%
0.63
+1.46%
0.62
+0.00%
0.62
Investments And Advances
0.00
-100.00%
5.02
+11.55%
4.50
0.00
Other Non Current Assets
5.34
+597.78%
0.77
-66.20%
2.26
-23.62%
2.96
Total Liabilities Net Minority Interest
305.93
+3.88%
294.51
+20.94%
243.52
+8.24%
224.98
Current Liabilities
46.42
+1.02%
45.95
+47.22%
31.21
+30.51%
23.92
Payables And Accrued Expenses
27.72
+1.04%
27.43
+65.87%
16.54
+33.55%
12.38
Payables
12.14
+11.03%
10.93
+67.81%
6.51
+17.86%
5.53
Accounts Payable
12.14
+11.03%
10.93
+67.81%
6.51
+17.86%
5.53
Current Accrued Expenses
15.58
-5.58%
16.50
+64.60%
10.02
+46.21%
6.86
Pensionand Other Post Retirement Benefit Plans Current
13.52
+27.87%
10.57
-2.26%
10.81
+30.97%
8.26
Other Current Liabilities
5.18
-34.76%
7.95
+105.91%
3.86
+17.83%
3.28
Total Non Current Liabilities Net Minority Interest
259.51
+4.40%
248.56
+17.08%
212.31
+5.59%
201.06
Long Term Debt And Capital Lease Obligation
128.33
+4.01%
123.39
+24.14%
99.39
+0.27%
99.12
Long Term Debt
122.21
+0.39%
121.73
+23.52%
98.55
+1.04%
97.54
Long Term Capital Lease Obligation
6.12
+270.36%
1.65
+95.85%
0.84
-46.78%
1.59
Tradeand Other Payables Non Current
3.90
+2.95%
3.79
+18.69%
3.19
+5.83%
3.02
Non Current Deferred Liabilities
—
—
—
3.02
Non Current Deferred Taxes Liabilities
—
—
—
3.02
Other Non Current Liabilities
—
—
—
98.92
Stockholders Equity
-105.47
-1098.16%
-8.80
+86.50%
-65.21
+27.02%
-89.36
Common Stock Equity
-105.47
-1098.16%
-8.80
+86.50%
-65.21
+27.02%
-89.36
Capital Stock
0.13
+15.65%
0.12
+29.21%
0.09
+41.27%
0.06
Common Stock
0.13
+15.65%
0.12
+29.21%
0.09
+41.27%
0.06
Share Issued
48.35
+14.49%
42.23
+29.98%
32.49
+40.47%
23.13
Ordinary Shares Number
48.35
+14.49%
42.23
+29.98%
32.49
+40.47%
23.13
Additional Paid In Capital
854.09
+7.13%
797.25
+29.84%
614.03
+25.88%
487.79
Retained Earnings
-959.72
-19.04%
-806.22
-18.68%
-679.35
-17.72%
-577.10
Gains Losses Not Affecting Retained Earnings
0.02
-66.07%
0.06
+366.67%
0.01
+111.21%
-0.11
Other Equity Adjustments
0.02
-66.07%
0.06
+366.67%
0.01
+111.21%
-0.11
Total Equity Gross Minority Interest
-105.47
-1098.16%
-8.80
+86.50%
-65.21
+27.02%
-89.36
Total Capitalization
16.74
-85.18%
112.93
+238.74%
33.34
+307.77%
8.18
Working Capital
139.61
-39.35%
230.19
+66.83%
137.97
+31.42%
104.99
Invested Capital
16.74
-85.18%
112.93
+238.74%
33.34
+307.77%
8.18
Total Debt
128.33
+4.01%
123.39
+24.14%
99.39
+0.27%
99.12
Net Debt
11.46
—
3.55
-91.58%
42.13
Capital Lease Obligations
6.12
+270.36%
1.65
+95.85%
0.84
-46.78%
1.59
Net Tangible Assets
-105.47
-1098.16%
-8.80
+86.50%
-65.21
+27.02%
-89.36
Tangible Book Value
-105.47
-1098.16%
-8.80
+86.50%
-65.21
+27.02%
-89.36
Available For Sale Securities
—
5.02
+11.55%
4.50
—
Derivative Product Liabilities
127.28
+4.85%
121.39
+10.63%
109.72
+10.92%
98.92
Investmentin Financial Assets
0.00
-100.00%
5.02
+11.55%
4.50
0.00
Other Inventories
—
-0.02
-159.38%
0.03
+6.67%
0.03
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-162.44
-67.87%
-96.77
-26.70%
-76.38
+12.77%
-87.56
Cash Flow From Continuing Operating Activities
-162.44
-67.87%
-96.77
-26.70%
-76.38
+12.77%
-87.56
Net Income From Continuing Operations
-153.49
-20.98%
-126.87
-24.09%
-102.24
+6.87%
-109.78
Depreciation Amortization Depletion
2.41
+103.29%
1.19
-30.44%
1.71
-6.16%
1.82
Depreciation
2.41
+103.29%
1.19
-30.44%
1.71
-6.16%
1.82
Depreciation And Amortization
2.41
+103.29%
1.19
-30.44%
1.71
-6.16%
1.82
Other Non Cash Items
3.60
+376.17%
-1.30
-228.70%
1.01
-61.36%
2.62
Stock Based Compensation
11.96
-8.77%
13.11
+40.30%
9.34
-11.69%
10.58
Operating Gains Losses
2.87
-81.00%
15.08
+31.06%
11.50
-17.87%
14.01
Gain Loss On Investment Securities
2.87
-81.00%
15.08
+31.06%
11.50
-17.87%
14.01
Change In Working Capital
-27.91
-665.86%
4.93
+47.87%
3.34
+152.90%
-6.31
Change In Receivables
-12.78
-163.02%
-4.86
-77.40%
-2.74
-177.51%
-0.99
Changes In Account Receivables
-12.78
-163.02%
-4.86
-77.40%
-2.74
-177.51%
-0.99
Change In Inventory
-7.24
-103.63%
-3.55
-163.65%
-1.35
-272.38%
-0.36
Change In Prepaid Assets
-5.83
-505.78%
1.44
+75.12%
0.82
+122.61%
-3.63
Change In Payables And Accrued Expense
3.23
-69.65%
10.65
+58.66%
6.71
+322.14%
1.59
Change In Accrued Expense
2.95
+1307.38%
-0.24
-109.54%
2.56
+95.34%
1.31
Change In Payable
0.29
-97.37%
10.89
+162.17%
4.16
+1378.65%
0.28
Change In Account Payable
0.29
-97.37%
10.89
+162.17%
4.16
+1378.65%
0.28
Change In Other Working Capital
-0.00
-102.04%
0.05
—
—
Change In Other Current Assets
-4.57
-415.53%
1.45
+106.41%
0.70
+155.32%
-1.27
Change In Other Current Liabilities
-0.73
-207.59%
-0.24
+70.78%
-0.81
+50.91%
-1.65
Investing Cash Flow
61.56
+398.64%
-20.61
-2062.96%
-0.95
-189.91%
1.06
Cash Flow From Continuing Investing Activities
61.56
+398.64%
-20.61
-2062.96%
-0.95
-189.91%
1.06
Net PPE Purchase And Sale
-0.29
+2.03%
-0.29
-52.06%
-0.19
+23.62%
-0.25
Purchase Of PPE
-0.29
+2.03%
-0.29
-52.06%
-0.19
+23.62%
-0.25
Capital Expenditure
-0.29
+2.03%
-0.29
-52.06%
-0.19
+23.62%
-0.25
Net Investment Purchase And Sale
61.85
+404.40%
-20.32
-2576.94%
-0.76
-157.76%
1.31
Purchase Of Investment
-77.40
+39.54%
-128.02
-156.91%
-49.83
+20.91%
-63.01
Sale Of Investment
139.25
+29.29%
107.70
+119.48%
49.07
-23.71%
64.32
Financing Cash Flow
39.92
-79.49%
194.62
+66.44%
116.93
+20.38%
97.13
Cash Flow From Continuing Financing Activities
39.92
-79.49%
194.62
+66.44%
116.93
+20.38%
97.13
Net Issuance Payments Of Debt
-1.85
-107.58%
24.49
0.00
-100.00%
95.78
Issuance Of Debt
0.00
-100.00%
24.49
0.00
-100.00%
95.78
Repayment Of Debt
-1.85
0.00
—
—
Long Term Debt Issuance
0.00
-100.00%
24.49
0.00
-100.00%
95.78
Long Term Debt Payments
-1.85
0.00
—
—
Net Long Term Debt Issuance
-1.85
-107.58%
24.49
0.00
-100.00%
95.78
Net Common Stock Issuance
39.80
-73.67%
151.17
+124.43%
67.36
0.00
Proceeds From Stock Option Exercised
1.97
-89.60%
18.96
-61.75%
49.57
+3180.81%
1.51
Net Other Financing Charges
—
—
—
-0.16
Changes In Cash
-60.97
-178.93%
77.24
+95.04%
39.60
+272.37%
10.63
Beginning Cash Position
173.06
+80.61%
95.82
+70.44%
56.22
+23.33%
45.59
End Cash Position
112.09
-35.23%
173.06
+80.61%
95.82
+70.44%
56.22
Free Cash Flow
-162.73
-67.66%
-97.06
-26.76%
-76.57
+12.80%
-87.81
Amortization Of Securities
-1.88
+35.14%
-2.89
-179.59%
-1.03
-107.63%
-0.50
Common Stock Issuance
39.80
-73.67%
151.17
+124.43%
67.36
0.00
Issuance Of Capital Stock
39.80
-73.67%
151.17
+124.43%
67.36
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category